Quick filters

67 trials match your criteria

Dermatomyositis+1

Recruiting

Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Study on the Safety and Effects of Cipaglucosidase Alfa and Miglustat for Children with Infantile-onset Pompe Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years

Efficacy and Safety of Givinostat for Non-Ambulant Patients with Duchenne Muscular Dystrophy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years

Study on Gene Therapy with AAV9.LAMP2B for Male Patients with Danon Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years

Safety and dose‑finding study of CD19‑CART01 in patients with SLE, SSc, DM/PM, IMNM, AAV, MG, NMOSD, or chronic GVHD

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years

Muscular dystrophy

Not yet recruiting

Long-Term Safety and Efficacy of Oral Ribitol in Participants with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years

Duchenne muscular dystrophy

Not yet recruiting

Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Intravenous sgt-003 in Ambulatory Male Patients with Duchenne Muscular Dystrophy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years

Autoimmune myositis

Not yet recruiting

A study to evaluate the safety and effectiveness of CABA-201, fludarabine, and cyclophosphamide in patients with active inflammatory myopathy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Muscular dystrophy

Not yet recruiting

Study on the Effectiveness of Deflazacort in Treating LMNA-related Congenital Muscular Dystrophy in Adults and Children

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years

powered byClinicalTrials.eu